Literature DB >> 28408391

LMNA-associated partial lipodystrophy: anticipation of metabolic complications.

Isabelle Jeru1,2, Camille Vatier2,3, Marie-Christine Vantyghem4, Olivier Lascols1,2, Corinne Vigouroux1,2,3.   

Abstract

BACKGROUND: Type-2 familial partial lipodystrophy (FPLD2) is a rare autosomal dominant lipodystrophic disorder due to mutations in LMNA encoding lamin A/C, a key epigenetic regulator. FPLD2 severity is determined by the occurrence of metabolic complications, especially diabetes and hypertriglyceridaemia. We evaluated the disease history and severity over generations.
METHODS: This retrospective study of the largest cohort of patients with FPLD2 reported to date investigates 85 patients from 24 families comprising three generations (G1: n=39; G2: n=41; G3: n=5).
RESULTS: Lipodystrophy appears with the same characteristics and at the same age in first generation (G1;18.6±1.5 years) and second generation (G2;15.9±0.8 years). Despite similar body mass index (23.7±0.6 vs 23.8±0.6 kg/m2), the mean delay between the onset of lipodystrophy and diabetes was far shorter in G2 (10.5±2.4 years) than in G1 (29.0±3.5 years) (p=0.0002). The same is true for the delay preceding hypertriglyceridaemia (G2: 4.5±1.4; G1: 19.3±3.2 years) (p=0.002), revealing an anticipation phenomenon. Observations in G3, and analysis within each family of disease history and diagnostic procedures, confirmed this result.
CONCLUSIONS: This study is a rare example of anticipation unrelated to a trinucleotide expansion. Discovery of this early occurrence of metabolic complications in young generations underlines the utility of presymptomatic genetic diagnosis, with careful metabolic screening and preventive lifestyle in all at-risk individuals. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Anticipation; Diabetes; Hypertriglyceridaemia; LMNA; lipodystrophy

Mesh:

Substances:

Year:  2017        PMID: 28408391     DOI: 10.1136/jmedgenet-2016-104437

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  5 in total

1.  Cardiac phenotype in familial partial lipodystrophy.

Authors:  Abdelwahab Jalal Eldin; Baris Akinci; Andre Monteiro da Rocha; Rasimcan Meral; Ilgin Yildirim Simsir; Suleyman Cem Adiyaman; Ebru Ozpelit; Nicole Bhave; Ramazan Gen; Banu Yurekli; Nilufer Ozdemir Kutbay; Zeynep Siklar; Adam H Neidert; Rita Hench; Marwan K Tayeh; Jeffrey W Innis; Jose Jalife; Hakan Oral; Elif A Oral
Journal:  Clin Endocrinol (Oxf)       Date:  2021-02-22       Impact factor: 3.523

Review 2.  Lipodystrophic syndromes due to LMNA mutations: recent developments on biomolecular aspects, pathophysiological hypotheses and therapeutic perspectives.

Authors:  Corinne Vigouroux; Anne-Claire Guénantin; Camille Vatier; Emilie Capel; Caroline Le Dour; Pauline Afonso; Guillaume Bidault; Véronique Béréziat; Olivier Lascols; Jacqueline Capeau; Nolwenn Briand; Isabelle Jéru
Journal:  Nucleus       Date:  2018-01-01       Impact factor: 4.197

3.  Unraveling LMNA Mutations in Metabolic Syndrome: Cellular Phenotype and Clinical Pitfalls.

Authors:  Camille Desgrouas; Alice-Anaïs Varlet; Anne Dutour; Damien Galant; Françoise Merono; Nathalie Bonello-Palot; Patrice Bourgeois; Adèle Lasbleiz; Cathy Petitjean; Patricia Ancel; Nicolas Levy; Catherine Badens; Bénédicte Gaborit
Journal:  Cells       Date:  2020-01-28       Impact factor: 6.600

4.  Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins).

Authors:  H Mosbah; B Donadille; M C Vantyghem; C Vigouroux; C Vatier; S Janmaat; M Atlan; C Badens; P Barat; S Béliard; J Beltrand; R Ben Yaou; E Bismuth; F Boccara; B Cariou; M Chaouat; G Charriot; S Christin-Maitre; M De Kerdanet; B Delemer; E Disse; N Dubois; B Eymard; B Fève; O Lascols; P Mathurin; E Nobécourt; A Poujol-Robert; G Prevost; P Richard; J Sellam; I Tauveron; D Treboz; B Vergès; V Vermot-Desroches; K Wahbi; I Jéru
Journal:  Orphanet J Rare Dis       Date:  2022-04-19       Impact factor: 4.303

Review 5.  Lipodystrophic laminopathies: Diagnostic clues.

Authors:  Cristina Guillín-Amarelle; Antía Fernández-Pombo; Sofía Sánchez-Iglesias; David Araújo-Vilar
Journal:  Nucleus       Date:  2018-01-01       Impact factor: 4.197

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.